Pharmacological therapy for acute respiratory distress syndrome

Raksha Jain, Anthony DalNogare

Research output: Contribution to journalReview articlepeer-review

55 Scopus citations


Acute respiratory distress syndrome (ARDS) is an inflammatory process caused by a variety of direct and indirect injuries to the lungs. Despite improvements in supportive care and advances in ventilator management, mortality in patients with ARDS remains high. Multiple pharmacological interventions have been investigated but have not shown improved survival. Clinical trials using corticosteroids, prostaglandins, nitric oxide, prostacyclin, surfactant, lisofylline, ketoconazole, N-acetylcysteine, and fish oil have been unable to show a statistically significant improvement in patient mortality. As more is understood about the pathophysiology of ARDS, treatment strategies statistically as increasing alveolar fluid clearance through activation of sodium channels, enhancing repair of alveolar epithelium with growth factors, inhibiting fibrin deposition, blocking proinflammatory transcription factors, preventing the effect of potent vasocontrictors such as endothelin, and using antibodies against key inflammatory cytokines are being explored. This review focuses on the pharmacological treatments studied clinically, proposed reasons for their lack of success, and new concepts emerging in ARDS therapy.

Original languageEnglish (US)
Pages (from-to)205-212
Number of pages8
JournalMayo Clinic Proceedings
Issue number2
StatePublished - Feb 2006

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Pharmacological therapy for acute respiratory distress syndrome'. Together they form a unique fingerprint.

Cite this